Research & Literature

Porphyria Cutanea Tarda Masquerading as Epidermolysis Bullosa Acquisita: A Report of Two Cases.

Deen K, Wu J

Case reports in dermatology 2015; (7(2)):129-35 doi:10.1159/000435830.

Troxis necrosis, a novel mechanism for drug-induced hepatitis secondary to immunomodulatory therapy.

Wei CH, Penunuri A, Karpouzas G, et al.

Experimental and molecular pathology 2015; (99(2)):341-3.

Human immunodeficiency virus and risk of porphyria cutanea tarda: a possible association examined in a large hospital.

Aguilera P, Laguno M, To-Figueras J

Photodermatology, photoimmunology & photomedicine 2016; (32(2)):93-7 doi:10.1111/phpp.12222.

Human Immunodeficiency Virus Associated Sporadic Nonfamilial Porphyria Cutanea Tarda.

Guha SK, Bandyopadhyay D, Saha A, Lal NR

Indian journal of dermatology 2016; (61(3)):318-20 doi:10.4103/0019-5154.182424.

Clinical applications of therapeutic phlebotomy.

Kim KH, Oh KY

Journal of blood medicine 2016; (7()):139-44 doi:10.2147/JBM.S108479.

Porphyria cutanea tarda in a HIV- positive patient.

Franzon VA, Mikilita ES, Camelo FH, Camargo R

Anais brasileiros de dermatologia 2016; (91(4)):520-3.

The D519G Polymorphism of Glyceronephosphate O-Acyltransferase Is a Risk Factor for Familial Porphyria Cutanea Tarda.

Farrell CP, Overbey JR, Naik H, et al.

PloS one 2016; (11(9)):e0163322 doi:10.1371/journal.pone.0163322.

Hepatic porphyria: A narrative review.

Arora S, Young S, Kodali S, Singal AK

Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology 2016; (35(6)):405-418 doi:10.1007/s12664-016-0698-0.

[Hepatocellular carcinoma surveillance].

Costentin C

Presse medicale (Paris, France : 1983) 2017; (46(4)):381-385 doi:10.1016/j.lpm.2016.11.006.

Porphyria cutanea tarda: an intriguing genetic disease and marker.

Handler NS, Handler MZ, Stephany MP, et al.

International journal of dermatology 2017; (56(6)):e106-e117 doi:10.1111/ijd.13580.

Dermatologic Manifestations of Chronic Hepatitis C Infection.

Sayiner M, Golabi P, Farhat F, Younossi ZM

Clinics in liver disease 2017; (21(3)):555-564 doi:10.1016/j.cld.2017.03.010.

Disappearance of multiple hyperechoic liver nodules in sporadic porphyria cutanea tarda after treatment with ledipasvir/sofosbuvir for hepatitis C.

Takata K, Shakado S, Sakamoto K, et al.

Clinical journal of gastroenterology 2017; (10(5)):459-463 doi:10.1007/s12328-017-0772-x.

Urinary metabolic profiling of asymptomatic acute intermittent porphyria using a rule-mining-based algorithm.

Luck M, Schmitt C, Talbi N, et al.

Metabolomics : Official journal of the Metabolomic Society 2018; (14(1)):10 doi:10.1007/s11306-017-1305-9.

Porphyria cutanea tarda and hepatoerythropoietic porphyria: Identification of 19 novel uroporphyrinogen III decarboxylase mutations.

Weiss Y, Chen B, Yasuda M, et al.

Molecular genetics and metabolism 2019; (128(3)):363-366 doi:10.1016/j.ymgme.2018.11.013.

Porphyria cutanea tarda: a case report.

Usta Atmaca H, Akbas F

Journal of medical case reports 2019; (13(1)):17 doi:10.1186/s13256-018-1956-9.

Porphyria cutanea tarda: Recent update.

Singal AK

Molecular genetics and metabolism 2019; (128(3)):271-281 doi:10.1016/j.ymgme.2019.01.004.

Porphyria cutanea tarda increases risk of hepatocellular carcinoma and premature death: a nationwide cohort study.

Baravelli CM, Sandberg S, Aarsand AK, Tollånes MC

Orphanet journal of rare diseases 2019; (14(1)):77 doi:10.1186/s13023-019-1051-3.

Blistering Disease During the Treatment of Chronic Hepatitis C With Ledipasvir/Sofosbuvir.

Cash J, Skinner A, Cash S, et al.

Federal practitioner : for the health care professionals of the VA, DoD, and PHS 2019; (36(Suppl 2)):S11-S13.

Epidemiology of cutaneous porphyria in Israel: a nationwide cohort study.

Edel Y, Mamet R, Snast I, et al.

Journal of the European Academy of Dermatology and Venereology : JEADV 2020; (34(1)):184-187 doi:10.1111/jdv.15769.

Increased mortality in patients with porphyria cutanea tarda-A nationwide cohort study.

Christiansen AL, Brock A, Bygum A, et al.

Journal of the American Academy of Dermatology 2020; (83(3)):817-823 doi:10.1016/j.jaad.2019.07.082.

Case for diagnosis. Sclerodermiform manifestations of porphyria cutanea tarda secondary to hepatitis C.

Calado JOA, Bastos LMH, Miot HA

Anais brasileiros de dermatologia 2019; (94(4)):479-481 doi:10.1590/abd1806-4841.20198681.

A case of porphyria cutanea tarda in the setting of hepatitis C infection and tobacco usage.

Lederhandler M, Chen L, Meehan SA, et al.

Dermatology online journal 2019; (25(12)).

Resolution of subclinical porphyria cutanea tarda after hepatitis C eradication with direct-acting anti-virals.

Sastre L, To-Figueras J, Lens S, et al.

Alimentary pharmacology & therapeutics 2020; (51(10)):968-973 doi:10.1111/apt.15703.

Sporadic Porphyria Cutanea Tarda as the Initial Manifestation of Hereditary Hemochromatosis.

Edwards MV, Ray JM, Bacon BR

ACG case reports journal 2019; (6(11)):e00247 doi:10.14309/crj.0000000000000247.

Porphyria cutanea tarda unmasked by supratherapeutic estrogen during gender-affirming hormone therapy.

Jackson Cullison SR, Jedrych JJ, James AJ

JAAD case reports 2020; (6(7)):675-678 doi:10.1016/j.jdcr.2020.04.036.

Hydroxychloroquine in Dermatology and Beyond: Recent Update.

Sardana K, Sinha S, Sachdeva S

Indian dermatology online journal 2020; (11(3)):453-464 doi:10.4103/idoj.IDOJ_280_20.

Porphyria cutanea tarda precipitated by ovarian stimulation during oocyte retrieval in a genetically susceptible female.

Rasheed E, Savage S, Walsh E, et al.

Annals of clinical biochemistry 2021; (58(3)):251-256 doi:10.1177/0004563220988037.

Porphyria: awareness is the key to diagnosis!

Heymans B, Meersseman W

Acta clinica Belgica 2022; (77(3)):703-709 doi:10.1080/17843286.2021.1918876.

Evolution of HCV associated porphyria cutanea tarda after HCV sustained virologic response by direct acting antivirals.

García-Fraile LJ, García-Buey L, Alonso Cerezo C, et al.

Gastroenterologia y hepatologia 2022; (45(4)):249-255 doi:10.1016/j.gastrohep.2021.09.001.

Porphyria cutanea tarda and patterns of long-term sick leave and disability pension: a 24-year nationwide matched-cohort study.

Baravelli CM, Aarsand AK, Sandberg S, Tollånes MC

Orphanet journal of rare diseases 2022; (17(1)):72 doi:10.1186/s13023-022-02201-3.

Ledipasvir/Sofosbuvir Is Effective as Sole Treatment of Porphyria Cutanea Tarda with Chronic Hepatitis C.

Bonkovsky HL, Rudnick SP, Ma CD, et al.

Digestive diseases and sciences 2023; (68(6)):2738-2746 doi:10.1007/s10620-023-07859-8.

A Case Report of Porphyria Cutanea Tarda with Hepatitis-C Virus Co-infection.

Hasan MN, Bhuiyan MR, Ferdous SH, et al.

Mymensingh medical journal : MMJ 2023; (32(2)):584-586.

Bullous lesions following phototherapy in a newborn.

Toscano MM, Cintra FF, Resende LO, et al.

Einstein (Sao Paulo, Brazil) 2023; (21()):eRC0256 doi:10.31744/einstein_journal/2023RC0256.

Case Report: Treatment of porphyria cutanea tarda with low dose hydroxychloroquine.

Awad A, Nirenberg A, Sinclair R

F1000Research 2022; (11()):945 doi:10.12688/f1000research.124022.1.

A Rare Case of Hereditary Hemochromatosis Presenting With Porphyria Cutanea Tarda.

Varada N, Tun KM, Chang MJ, et al.

Cureus 2023; (15(7)):e41299 doi:10.7759/cureus.41299.

Porphyria cutanea tarda: an under-recognised manifestation of haemochromatosis.

Goh JW, Ong CK, Abdullah KM

BMJ case reports 2023; (16(9)) doi:10.1136/bcr-2022-253203.

Drug-Induced Pseudoporphyria: A Case Report.

Jangid SD, Saoji V, Madke B, Bhatt DM

Cureus 2024; (16(4)):e57574 doi:10.7759/cureus.57574.

Understanding Hepatic Porphyrias: Symptoms, Treatments, and Unmet Needs.

Balogun O, Nejak-Bowen K

Seminars in liver disease 2024; (44(2)):209-225 doi:10.1055/s-0044-1787076.

[An overview of porphyrias].

Lindemann H, Diehl-Wiesenecker E, Gerischer L, Frank J

Dermatologie (Heidelberg, Germany) 2024; (75(7)):539-547 doi:10.1007/s00105-024-05370-3.

Practical recommendations for biochemical and genetic diagnosis of the porphyrias.

Aarsand AK, To-Figueras J, Whatley S, et al.

Liver international : official journal of the International Association for the Study of the Liver 2025; (45(3)):e16012 doi:10.1111/liv.16012.

A rare case of meloxicam-induced pseudoporphyria.

Benandi K, Sieving D, Wolf K

Dermatology online journal 2024; (30(2)) doi:10.5070/D330263593.

Clinical Characteristics and Inciting Agents for Pseudoporphyria: The Mayo Clinic Experience, 1996-2020.

Kumar AB, Asamoah EM, Wetter DA, et al.

Advances in skin & wound care 2024; (37(8)):406-411 doi:10.1097/ASW.0000000000000176.

Novel UROD mutation for porphyria cutanea tarda, type 2: a case report.

Soufleris S, Moore M, Phillips JD, et al.

AME case reports 2024; (8()):67 doi:10.21037/acr-23-66.

Porphyria cutanea tarda triggered by hepatitis-E virus.

Hrabak P, Benesova K, Zahorakova D, Bruha R

Bratislavske lekarske listy 2024; (125(10)):587-588 doi:10.4149/BLL_2024_91.

Porphyria Cutanea Tarda in a Patient With Hereditary Hemochromatosis: A Complex Overlap Disorder.

DeMaria BL, Franke AJ

Cureus 2024; (16(11)):e74091 doi:10.7759/cureus.74091.

Porphyria cutanea tarda: a unique iron-related disorder.

Leaf RK, Dickey AK

Hematology. American Society of Hematology. Education Program 2024; (2024(1)):450-456 doi:10.1182/hematology.2024000664.

EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma.

Journal of hepatology 2025; (82(2)):315-374 doi:10.1016/j.jhep.2024.08.028.

A Health Economic Evaluation of Routine Hepatocellular Carcinoma Surveillance for People with Compensated Cirrhosis to Support Australian Clinical Guidelines.

Worthington J, He E, Caruana M, et al.

MDM policy & practice 2025; (10(1)):23814683251344962 doi:10.1177/23814683251344962.

[Porphyria cutanea tarda].

Mistegård J, Christiansen AL, Vestergaard C, et al.

Ugeskrift for laeger 2025; (187(38)) doi:10.61409/V11240832.

[Porphyria cutanea tarda and hepatitis C infection].

Stockmann A, Christiansen AL, Lorentzen HF

Ugeskrift for laeger 2025; (187(38)) doi:10.61409/V01250056.

Pseudoporphyria triggered by ultraviolet A radiation exposure: the under-reported role of sunbeds and nail lamps.

Fostier W, Lye J, Alexander MD, et al.

Clinical and experimental dermatology 2026; (51(3)):473-475 doi:10.1093/ced/llaf475.

Stability of plasma and erythrocyte porphyrins: implications for diagnosis and monitoring of erythropoietic protoporphyria.

Schulenburg-Brand D, Maw K, Bentley LA, et al.

Journal of clinical pathology 2026; (79(3)):206-211 doi:10.1136/jcp-2025-210393.